UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

January 23, 2018

Date of Report (date of earliest event reported)   

 

 

Cancer Capital Corporation

(Exact name of Registrant as specified in its charter)

 

Nevada 000-32363 91-1803648
(State or other jurisdiction of incorporation)

(Primary Standard Industrial

Classification Code Number)

(IRS Employer Identification No.)
     

 

2157 S. Lincoln Street, Suite 200

Salt Lake City, Utah 84106

Phone: (801) 323-2395

 

 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

 

 

Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).

 

Emerging Growth Company ☑

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o

 

 
 

 

SECTION 4 - MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS

 

ITEM 4.01  CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT

 

On January 23, 2018, the Company dismissed Pritchett, Siler & Hardy, PC (“PSH”) as its independent registered accounting firm and engaged Heaton & Company, PLLC, dba Pinnacle Accountancy Group of Utah, as its new independent registered accounting firm.

 

Since PSH’s appointment as our independent registered accounting firm on March 13, 2014 and through January 23, 2018, which included its audits of our financial statements for the years ended December 31, 2016 and 2015, there were (i) no disagreements between the Company and PSH on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement, if not resolved to the satisfaction of PSH, would have caused PSH to make reference thereto in their reports on the financial statements for such years, and (ii) no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K.

 

The Company provided PSH with a copy of this Form 8-K and requested that PSH furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not PSH agrees with the above statements. A copy of such letter, dated January 23, 2018, is attached as Exhibit 16.1.

 

During years ended December 31, 2016 and 2015, and in the subsequent interim period through January 23, 2018, the Company has not consulted with Heaton & Company regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that PSH concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

 

 

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

 

ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits.

 

     

Exhibit Number

  Description
     
16.1   Letter from Pritchett Siler & Hardy, PC dated January 23, 2018

 

 

     

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date:  January 23, 2018 Cancer Capital Corporation  
       
       
  By:   /s/ John W. Peters  
    John W. Peters  
    President  

 

Cancer Capital (PK) (USOTC:CNCL)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Cancer Capital (PK) Charts.
Cancer Capital (PK) (USOTC:CNCL)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Cancer Capital (PK) Charts.